Membranous-cytoplasmic EGFR expression was shown to be a poor prognostic factor and could define a CCRCC subgroup with poor prognosis that should be responsive to anti-EGFR therapies. The gene discussed is EGFR; the disease is nonpapillary renal cell carcinoma.